Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

Sponsor
British Columbia Cancer Agency
Study ID
NCT04273061
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Atezolizumab — DRUG
    1200 mg by intravenous infusion every 3 weeks as tolerated

Study Details

This study will investigate the effects of atezolizumab on select cancer types in people whose analysis of tumour DNA and RNA indicates they may be sensitive to atezolizumab. This study aims to determine if the information from the cancer genome analysis corresponds with the effects of atezolizumab on individuals and their cancer. This is a Phase 2 study, which is undertaken after preliminary safety testing on a drug is completed, and will involve approximately 50 participants. Participants are assigned to one of 3 cohorts based on their primary tumour type: gastrointestinal (GI), sarcoma, and 'other' cancer types. Participants in all cohorts will receive the same dose of atezolizumab (1200 mg every 3 weeks). Participants continue on treatment until they no longer may benefit from the treatment or they decide to stop treatment.

Key Dates

First listed
Feb 17, 2020
Start date
Jun 17, 2020
Status verified
Sep 2026
Primary completion
Oct 31, 2027
Completion
Oct 31, 2027

Study Design

Enrollment
50 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: GI Cohort
    Cohort of participants whose primary tumour type is gastrointestinal (including pancreas and hepatobiliary).
  • Experimental: Sarcoma Cohort
    Cohort of participants whose primary tumour type is sarcoma.
  • Experimental: Other Cohort
    Cohort of participants whose primary tumour type is not classified as one of the other study arms. This cohort includes participants with head and neck, breast, lung, genitourinary (GU), gynecological, skin, primary unknown, or rare cancers.

Primary Outcome Measure

Overall response rate (ORR) for the study cohort, as defined by RECIST 1.1 [ Time Frame: From the date of the screening scan (within 28 days of first dose) until the date of confirmed progression, withdrawal, or date of death, whichever comes first, assessed up to 54 months. ]

Central Contacts

Find similar trials

Nationwide
Breast cancer trialsHead and neck cancer trialsLung cancer trialsSkin cancer trialsOncology trialsBreast oncology trialsWomen's health trialsENT trialsLung oncology trialsLung disease trialsSkin cancer trialsDermatology trials

Related Studies